ESMO: Pfizer boosts Ibrance’s class with positive neutropenia data

Pfizer this week got some good Ibrance news, and it’s news that could benefit the medicine’s expanding class, too. A subanalysis from the drug giant’s PALOMA-2 trial, presented at th…
Read the full story: FiercePharma: Pharma